Caribou Biosciences Inc (NASDAQ: CRBU) on Tuesday, soared 14.49% from the previous trading day, before settling in for the closing price of $2.07. Within the past 52 weeks, CRBU’s price has moved between $0.66 and $3.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -33.41% annually for the last half of the decade. The company achieved an average annual earnings per share of 9.52%. With a float of $80.97 million, this company’s outstanding shares have now reached $93.00 million.
In an organization with 147 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 73.03%, operating margin of -2161.63%, and the pretax margin is -1954.67%.
Caribou Biosciences Inc (CRBU) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Caribou Biosciences Inc is 12.94%, while institutional ownership is 50.11%. The most recent insider transaction that took place on Mar 14 ’25, was worth 20,400. In this transaction President and CEO of this company bought 20,000 shares at a rate of $1.02, taking the stock ownership to the 3,369,395 shares. Before that another transaction happened on Feb 21 ’25, when Company’s Chief Legal Officer sold 3,564 for $1.35, making the entire transaction worth $4,811. This insider now owns 443,502 shares in total.
Caribou Biosciences Inc (CRBU) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 9.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.16% during the next five years compared to -33.41% drop over the previous five years of trading.
Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators
Caribou Biosciences Inc (CRBU) is currently performing well based on its current performance indicators. A quick ratio of 7.63 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of Caribou Biosciences Inc (CRBU)
Let’s dig in a bit further. During the last 5-days, its volume was 2.28 million. That was better than the volume of 1.33 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.21%.
During the past 100 days, Caribou Biosciences Inc’s (CRBU) raw stochastic average was set at 98.84%, which indicates a significant increase from 98.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.18 in the past 14 days, which was higher than the 0.11 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.29, while its 200-day Moving Average is $1.46. However, in the short run, Caribou Biosciences Inc’s stock first resistance to watch stands at $2.50. Second resistance stands at $2.62. The third major resistance level sits at $2.86. If the price goes on to break the first support level at $2.14, it is likely to go to the next support level at $1.90. Assuming the price breaks the second support level, the third support level stands at $1.78.
Caribou Biosciences Inc (NASDAQ: CRBU) Key Stats
Market capitalization of the company is 220.42 million based on 93,005K outstanding shares. Right now, sales total 9,990 K and income totals -149,110 K. The company made 2,350 K in profit during its latest quarter, and -39,990 K in sales during its previous quarter.
